

Reference list

Biacore™ systems

Biophysical techniques

Review

Renaud JP, Chung C, Danielson UH, et al. Biophysics in drug discovery: impact, challenges and opportunities. *Nature Reviews Drug Discovery*. 2016;15(10):679-698. doi:10.1038/nrd.2016.123.

Masson JF. Surface Plasmon Resonance Clinical Biosensors for Medical Diagnostics. *ACS Sensors*. 2017;2(1):16-30. doi:10.1021/acssensors.6b00763

Antigen binding

Seigner J, Zajc CU, Dötsch S, et al. Solving the mystery of the FMC63-CD19 affinity. *Scientific Reports*. 2023;13(1). doi:10.1038/s41598-023-48528-0

Ow SY, Kapp EA, Tomasetig V, et al. HDX-MS study on garadacimab binding to activated FXII reveals potential binding interfaces through differential solvent exposure. *mAbs*. 2023;15(1). doi:10.1080/19420862.2022.2163459

Benicky J, Sanda M, Brnakova Kennedy Z, et al. PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies. *Journal of Proteome Research*. 2020;20(1):485-497. doi:10.1021/acs.jproteome.0c00521

Kamat V, Boutot C, Rafique A, et al. High affinity human Fc specific monoclonal antibodies for capture kinetic analyses of antibody-antigen interactions. *Analytical Biochemistry*. 2021;640:114455-114455. doi:10.1016/j.ab.2021.114455

Frick R, Høydahl LS, Petersen J, et al. A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation. *Science Immunology*. 2021;6(62). doi:10.1126/sciimmunol.abg4925

Usui D, Inaba S, Kamatari YO, Ishiguro N, Oda M. Light-chain residue 95 is critical for antigen binding and multispecificity of monoclonal antibody G2. *Biochemical and Biophysical Research Communications*. 2017;490(4):1205-1209. doi:10.1016/j.bbrc.2017.06.183

Henry KA, Hiba Kandalafi, Lowden MJ, et al. A disulfide-stabilized human V L single-domain antibody library is a source of soluble and highly thermostable binders. *Molecular Immunology*. 2017;90:190-196. doi:10.1016/j.molimm.2017.07.006

Birch J, Hörður Kári Harðarson, Khan S, et al. Effect of repeat unit structure and molecular mass of lactic acid bacteria heteropolysaccharides on binding to milk proteins. *Carbohydrate polymers*. 2017;177:406-414. doi:10.1016/j.carbpol.2017.08.055

Wang W, Soriano B, Chen Q. Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance. *Analytical Biochemistry*. 2017;538:53-63. doi:10.1016/j.ab.2017.09.014

Molecular interactions with slow dissociation rate

Maxim, Mølck C, Henderson I, et al. Tralokinumab does not affect endogenous IL-13Rα2-mediated regulation of free IL-13. *JID Innov*. 2023;3(5):100214-100214. doi:10.1016/j.xjidi.2023.100214

Smith CR, Aranda R, Bobinski TP, et al. Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers. *Journal of Medicinal Chemistry*. 2022;65(3):1749-1766. doi:10.1021/acs.jmedchem.1c01900

Biotherapeutics

Review

Yang D, Singh A, Wu H, Kroe-Barrett R. Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics. *Analytical Biochemistry*. 2016;508:78-96. doi:10.1016/j.ab.2016.06.024

Federici M, Lubiniecki A, Manikwar P, Volkin DB. Analytical lessons learned from selected therapeutic protein drug comparability studies. *Biologicals*. 2013;41(3):131-147. doi:10.1016/j.biologicals.2012.10.001

Shih HH. Discovery Process for Antibody-Based Therapeutics. *Development of Antibody-Based Therapeutics*. Published online 2012:9-32. doi:10.1007/978-1-4419-5955-3_2

Willemsen-Seegers N, Joost C.M. Uitdehaag, Martine B.W. Prinsen, et al. Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. *Journal of Molecular Biology*. 2016;429(4):574-586. doi:10.1016/j.jmb.2016.12.019

Antibody screening

Emenike Kenechi Onyido, James D, Jezabel Garcia-Parra, et al. Elucidating Novel Targets for Ovarian Cancer Antibody-Drug Conjugate Development: Integrating In Silico Prediction and Surface Plasmon Resonance to Identify Targets with Enhanced Antibody Internalization Capacity. *Antibodies*. 2023;12(4):65-65. doi:10.3390/antib12040065

Shen Y, Wang Y, Jiang X, et al. Preparation and characterization of a high-affinity monoclonal antibody against human epididymis protein-4. *Protein Expression and Purification*. 2017;141:44-51. doi:10.1016/j.pep.2017.09.005

Vincent KJ, Zurini M. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates. *Biotechnology Journal*. 2012;7(12):1444-1450. doi: 10.1002/biot.201200250

Hearty S, Leonard P, O'Kennedy R. Measuring antibody-antigen binding kinetics using surface plasmon resonance. *Methods in Molecular Biology* (Clifton, NJ). 2012;907:411-442. doi:10.1007/978-1-61779-974-7_24

Schräml M, Leopold von Proff. Temperature-Dependent Antibody Kinetics as a Tool in Antibody Lead Selection. *Methods in molecular biology*. 2012;901:183-194. doi: 10.1007/978-1-61779-931-0_12

Schräml M, Biehl M. Kinetic Screening in the Antibody Development Process. *Methods in molecular biology*. 2012;901:171-181. doi:10.1007/978-1-61779-931-0_11

Kamat V, Rafique A. Extending the throughput of Biacore 4000 biosensor to accelerate kinetic analysis of antibody-antigen interaction. *Analytical Biochemistry*. 2017;530:75-86. doi:10.1016/j.ab.2017.04.020

Katsamba PS, Navrátilová I, Calderon-Cacia M, et al. Kinetic analysis of a high-affinity antibody/antigen interaction performed by multiple Biacore users. *Analytical Biochemistry*. 2006;352(2):208-221. doi:10.1016/j.ab.2006.01.034

Usui D, Inaba S, Kamatari YO, Ishiguro N, Oda M. Light-chain residue 95 is critical for antigen binding and multispecificity of monoclonal antibody G2. *Biochemical and Biophysical Research Communications*. 2017;490(4):1205-1209. doi:10.1016/j.bbrc.2017.06.183

Novel antibody formats

Bennett NR, Watson JL, Ragotte RJ, et al. Atomically accurate de novo design of single-domain antibodies. *bioRxiv* (Cold Spring Harbor Laboratory). Published online March 18, 2024. doi:10.1101/2024.03.14.585103

Lunn-Halbert MC, Laszlo GS, Erraiss S, et al. Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET® CC-96191. *Cancers*. 2024;16(5):877. doi:https://doi.org/10.3390/cancers16050877

Laurent Larivière, Julia Eva Krüger, Thomas von Hirschheydt, et al. End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations. *International Journal of Pharmaceutics X*. 2023;5:100157-100157. doi:10.1016/j.ijpx.2023.100157

Rossotti MA, van Faassen H, Tran AT, et al. Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models. *Communications Biology*. 2022;5(1):1-19. doi:10.1038/s42003-022-03866-z

Gassner C, Lipsmeier F, Metzger P, et al. Development and validation of a novel SPR-based assay principle for bispecific molecules. *Journal of Pharmaceutical and Biomedical Analysis*. 2015;102:144-149. doi:10.1016/j.jpba.2014.09.007

Stubenrauch K, Wessels U, Essig U, et al. An immunodepletion procedure advances free angiopoietin-2 determination in human plasma samples during anti-cancer therapy with bispecific anti-Ang2/VEGF CrossMab. *Journal of Pharmaceutical and Biomedical Analysis*. 2015;102:459-467. doi:10.1016/j.jpba.2014.10.005

Rauscher A, M. Frindel, C. Maurel, et al. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody. *Nuclear Medicine and Biology*. 2014;41:e66-e74. doi: 10.1016/j.nucmedbio.2013.12.012

Castoldi R, Jucknischke U, Pradel LP, et al. Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. *Protein Engineering Design & Selection*. 2012;25(10):551-560. doi:10.1093/protein/gzs048

Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. *PLoS One*. 2011;6(4):e17887. doi:10.1371/journal.pone.0017887

Meschendoerfer W, Gassner C, Lipsmeier F, Regula JT, Moelleken J. SPR-based assays enable the full functional analysis of bispecific molecules. *Journal of Pharmaceutical and Biomedical Analysis*. 2017;132:141-147. doi:10.1016/j.jpba.2016.09.028

PROTACs and molecular glues

Ma X, Leon B, Ornelas E, et al. Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon. *Scientific reports*. 2023;13(1). doi:10.1038/s41598-023-48606-3

Wurz RP, Rui H, Dellamaggiore K, et al. Affinity and cooperativity modulate ternary complex formation to drive targeted protein degradation. *Nature Communications*. 2023;14(1). doi:10.1038/s41467-023-39904-5

Roy MJ, Winkler S, Hughes SJ, et al. SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. *ACS Chemical Biology*. 2019;14(3):361-368. doi:10.1021/acschembio.9b00092

Kofink C, Trainor N, Mair B, et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. *Nature Communications*. 2022;13(1):5969. doi: 10.1038/s41467-022-33430-6 Epitope analysis

Schüchner S, Behm C, Mudrak I, Ogris E. The Myc tag monoclonal antibody 9E10 displays highly variable epitope recognition dependent on neighboring sequence context. *Science Signaling*. 2020;13(616):eaax9730. doi:10.1126/scisignal.aax9730

Lin JC, Ettinger RA, Schuman JT, et al. Six Amino Acid Residues in a 1200 Å² Interface Mediate Binding of Factor VIII to an IgG4κ Inhibitory Antibody. Doering CB, ed. *PLOS ONE*. 2015;10(1):e0116577. doi:10.1371/journal.pone.0116577

Nguyen PCT, Lewis KB, Ettinger RA, et al. High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance. *Blood*. 2014;123(17):2732-2739. doi:10.1182/blood-2013-09-527275

Abdiche YN, Malashock DS, Pinkerton A, Pons J. Exploring blocking assays using Octet, ProteOn, and Biacore biosensors. *Analytical Biochemistry*. 2009;386(2):172-180. doi:10.1016/j.ab.2008.11.038

Abdiche YN, Malashock DS, Pons J. Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. *Protein Science*. 2008;17(8):1326-1335. doi:10.1110/ps.035402.108

Abdiche YN, Yeung AY, Ni I, et al. Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One Another. Mantis NJ, ed. *PLOS ONE*. 2017;12(1):e0169535. doi:10.1371/journal.pone.0169535

Comparison with ELISA

Heinrich L, Tissot N, Hartmann DJ, Cohen R. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. *Journal of Immunological Methods*. 2010;352(1-2):13-22. doi:10.1016/j.jim.2009.10.002

FcγR – Review

Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. *Nature Reviews Drug Discovery*. 2012;11(7):527-540. doi:10.1038/nrd3746

Jiang XR, Song A, Bergelson S, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. *Nature Reviews Drug Discovery*. 2011;10(2):101-111. doi:10.1038/nrd3365

van der Poel CE, Spaapen RM, van de Winkel JGJ, Leusen JHW. Functional Characteristics of the High Affinity IgG Receptor, FcγRI. *The Journal of Immunology*. 2011;186(5):2699-2704. doi:10.4049/jimmunol.1003526

FcRn binding analysis

Sun H, Olsen HS, Mériegeon EY, et al. Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated disease. *Journal of Autoimmunity*. 2017;84:97-108. doi:10.1016/j.jaut.2017.08.004

Abdiche YN, Yeung YA, Chaparro-Riggers J, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. *mAbs*. 2015;7(2):331-343. doi:10.1080/19420862.2015.1008353

Stracke J, Emrich T, Rueger P, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. *mAbs*. 2014;6(5):1229-1242. doi:10.4161/mabs.29601

Gurbaxani BM, Miroslav Dostálek, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? *Molecular Immunology*. 2013;56(4):660-674. doi:10.1016/j.molimm.2013.05.008

Kelley RF, Meng YG. Methods to Engineer and Identify IgG1 Variants with Improved FcRn Binding or Effector Function. *Methods in molecular biology*. 2012;901:277-293. doi:10.1007/978-1-61779-931-0_18

Leonard P, Hayes CJ, R. O'Kennedy. Rapid temperature-dependent antibody ranking using Biacore A100. *Analytical Biochemistry*. 2010;409(2):290-292. doi:10.1016/j.ab.2010.10.036

Mieke Steukers, Schaus JM, Gool R van, et al. Rapid kinetic-based screening of human Fab fragments. *Journal of Immunological Methods*. 2006;310(1-2):126-135. doi:10.1016/j.jim.2006.01.002

Cooper MA. Label-free screening of bio-molecular interactions. *Analytical and Bioanalytical Chemistry*. 2003;377(5):834-842. doi:10.1007/s00216-003-2111-y

FcRI binding analysis

Kiyoshi M, Caaveiro JMM, Kawai T, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. *Nature Communications*. 2015;6(1). doi:10.1038/ncomms7866

FcγR – Fc structure and binding analysis

Wang W, Thiemann S, Chen Q. Utility of SPR technology in biotherapeutic development: Qualification for intended use. *Analytical Biochemistry*. 2022;654:114804. doi:10.1016/j.ab.2022.114804

Wessels U, Poehler A, Moheysen-Zadeh M, et al. Detection of antidrug antibodies against human therapeutic antibodies lacking Fc-effector functions by usage of soluble Fcγ receptor I. *Bioanalysis*. 2016;8(20):2135-2145. doi:10.4155/bio-2016-0182

Hayes JM, Frostell A, Cosgrave J, et al. Fc Gamma Receptor Glycosylation Modulates the Binding of IgG Glycoforms: A Requirement for Stable Antibody Interactions. *Journal of Proteome Research*. 2014;13(12):5471-5485. doi:10.1021/pr500414q

Zeck A, Pohlentz G, Schlothauer T, Peter-Katalinić J, Regula JT. Cell Type-Specific and Site Directed N-Glycosylation Pattern of FcγRIIIa. *Journal of Proteome Research*. 2011;10(7):3031-3039. doi:10.1021/pr1012653

Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab. *BioDrugs*. 2013;27(5):495-507. doi:10.1007/s40259-013-0036-3

Heider KH, Kiefer K, Zenz T, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. *Blood*. 2011;118(15):4159-4168. doi:10.1182/blood-2011-04-351932

Hulse J, Cox C. In Vitro Functional Testing Methods for Monoclonal Antibody Biosimilars. *Bioprocessintl.com*. Published June 2013. <https://www.bioprocessintl.com/monoclonal-antibodies/in-vitro-functional-testing-methods-for-monoclonal-antibody-biosimilars>

Shibata-Koyama M, Iida S, Okazaki A, et al. The N-linked oligosaccharide at Fc RIIIa Asn-45: an inhibitory element for high Fc RIIIa binding affinity to IgG glycoforms lacking core fucosylation. *Glycobiology*. 2008;19(2):126-134. doi:10.1093/glycob/cwn110

Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fc receptors and their polymorphic variants for human IgG subclasses. *Blood*. 2009;113(16):3716-3725. doi:10.1182/blood-2008-09-179754

J. Watzlawik. Prion Protein Helix1 Promotes Aggregation but Is Not Converted into beta-Sheet. *Journal of Biological Chemistry*. 2006;281(40):30242-30250. doi:10.1074/jbc.

Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment–FcγRIII complex. *Nature*. 2000;406(6793):267-273. doi:10.1038/35018508

Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcγ receptor in complex with Fc. *The Journal of Biological Chemistry*. 2001;276(19):16469-16477. doi:10.1074/jbc.M100350200

Hayes JM, Åsa Frostell, Karlsson R, et al. Identification of Fc Gamma Receptor Glycoforms That Produce Differential Binding Kinetics for Rituximab. *Mol Cell Proteomics*. 2017;16(10):1770-1788. doi:10.1074/mcp.m117.066944

Kinetics and PK

He C, Mansilla-Soto J, Nandish Khanra, et al. CD19 CAR antigen engagement mechanisms and affinity tuning. *Science Immunology*. 2023;8(81). doi:10.1126/sciimmunol.adf1426

Giardino Torchia ML, Gilbreth R, Merlino A, et al. Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy. *Cytotherapy*. 2022;24(7):720-732. doi:10.1016/j.jcyt.2022.03.008

Gutgsell AR, Gunnarsson A, Forssén P, Gordon E, Fornstedt T, Geschwindner S. Biosensor-Enabled Deconvolution of the Avidity-Induced Affinity Enhancement for the SARS-CoV-2 Spike Protein and ACE2 Interaction. *Analytical Chemistry*. 2021;94(2):1187-1194. doi:10.1021/acs.analchem.1c04372

Raghu D, Hamill P, Banaji A, McLaren A, Hsu YT. Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants. *Journal of Pharmaceutical Analysis*. 2021;12(1):58-64. doi:10.1016/j.jpha.2021.09.006

Leach A, Ilca FT, Akbar Z, et al. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. *Antiviral Research*. 2021;194:105147. doi:10.1016/j.antiviral.2021.105147

Moscetti I, Bizzarri AR, Cannistraro S. Binding kinetics of mutant p53R175H with wild type p53 and p63: A Surface Plasmon Resonance and Atomic Force Spectroscopy study. *Biophysical Chemistry*. 2017;228:55-61. doi:10.1016/j.bpc.2017.07.002

Igawa T, Ishii S, Tachibana T, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. *Nature Biotechnology*. 2010;28(11):1203-1207. doi:10.1038/nbt.1691

Fabini E, Danielson UH. Monitoring drug-serum protein interactions for early ADME prediction through Surface Plasmon Resonance technology. *Journal of Pharmaceutical and Biomedical Analysis*. 2017;144:188-194. doi:10.1016/j.jpba.2017.03.054

Schuetz DA, de Witte WEA, Wong YC, et al. Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. *Drug Discovery Today*. 2017;22(6):896-911. doi:10.1016/j.drudis.2017.02.002

Uitdehaag JCM, de Man J, Willemsen-Seegers N, et al. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. *Journal of Molecular Biology*. 2017;429(14):2211-2230. doi:10.1016/j.jmb.2017.05.014

Reagent qualification

O'Hara DM, Theobald V, Egan AC, et al. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents. *The AAPS journal*. 2012;14(2):316-328. doi:10.1208/s12248-012-9334-9

Staack RF, Stracke JO, Stubenrauch K, Vogel R, Schleyden J, Papadimitriou A. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents. *Bioanalysis*. 2011;3(5):523-534. doi:10.4155/bio.11.16

Late stage development and comparability

Watanabe H, Hayashida N, Sato M, Honda S. Biosensing-based quality control monitoring of the higher-order structures of therapeutic antibody domains. *Analytica Chimica Acta*. 2024;1303:342439-342439. doi:10.1016/j.aca.2024.342439

Baubek Spanov, Olaleye O, Tomés Mesurado, et al. Pertuzumab Charge Variant Analysis and Complementarity-Determining Region Stability Assessment to Deamidation. *Analytical Chemistry*. 2023;95(8):3951-3958. doi:10.1021/acs.analchem.2c03275

Jovic M, Cymer F. Qualification of a surface plasmon resonance assay to determine binding of IgG-type antibodies to complement component C1q. *Biologicals*. 2019;61:76-79. doi:10.1016/j.biologicals.2019.08.004

Rechlin C, Scheer F, Terwesten F, et al. Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis. *ACS chemical biology*. 2017;12(5):1397-1415. doi:10.1021/acscchembio.7b00062

Karlsson R, Pol E, Frostell Å. Comparison of surface plasmon resonance binding curves for characterization of protein interactions and analysis of screening data. *Analytical Biochemistry*. 2016;502:53-63. doi:10.1016/j.ab.2016.03.007

Pol E, Roos H, Markey F, Fredrik Elwinger, Shaw A, Karlsson R. Evaluation of calibration-free concentration analysis provided by Biacore™ systems. *Analytical Biochemistry*. 2016;510:88-97. doi:10.1016/j.ab.2016.07.009

Federici M, Lubiniecki A, Manikwar P, Volkin DB. Analytical lessons learned from selected therapeutic protein drug comparability studies. *Biologicals*. 2013;41(3):131-147. doi:10.1016/j.biologicals.2012.10.001

Upton R, Bell LN, Guy CP, et al. Orthogonal Assessment of Biotherapeutic Glycosylation: A Case Study Correlating N-Glycan Core Afucosylation of Herceptin with Mechanism of Action. *Anal Chem*. 2016;88(20):10259-10265. doi:10.1021/acs.analchem.6b02994

Magnenat L, Palmese A, Fremaux C, et al. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®. *mAbs*. 2016;9(1):127-139. doi:10.1080/19420862.2016.1259046

Hofmann HP, Kronthaler U, Fritsch C, et al. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel®). *Expert Opinion on Biological Therapy*. 2016;16(10):1185-1195. doi:10.1080/14712598.2016.1217329

Potency, concentration determination and calibration-free concentration analysis

Harvey IB, Cholewicki SD, Devyani Bhosale, et al. Overcoming Lot-to-Lot Variability in Protein Activity Using Epitope-Specific Calibration-Free Concentration Analysis. *Analytical Chemistry*. 2024;96(16):6275-6281. doi:10.1021/acs.analchem.3c05607

Zhang P, Tu GH, Wei J, et al. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity. *Cell Reports*. 2019;27(11):3117-3123.e5. doi:10.1016/j.celrep.2019.05.027

Karlsson R, Fridh V, Frostell Å. Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies. *Journal of Pharmaceutical Analysis*. 2018;8(2):138-146. doi:10.1016/j.jpha.2017.12.008

Pol E, Roos H, Markey F, Fredrik Elwinger, Shaw A, Karlsson R. Evaluation of calibration-free concentration analysis provided by BiacoreTM systems. *Analytical Biochemistry*. 2016;510:88-97. doi:10.1016/j.ab.2016.07.009

Visentin J, Minder L, Lee JH, Jean-Luc Taupin, Primo CD. Calibration free concentration analysis by surface plasmon resonance in a capture mode. *Talanta*. 2015;148:478-485. doi:10.1016/j.talanta.2015.11.025

Frostell Å, Mattsson A, Eriksson Å, et al. Nine surface plasmon resonance assays for specific protein quantitation during cell culture and process development. *Analytical Biochemistry*. 2015;477:1-9. doi:10.1016/j.ab.2015.02.010

Karlsson R. Biosensor binding data and its applicability to the determination of active concentration. *Biophysical Reviews*. 2016;8(4):347-358. doi:10.1007/s12551-016-0219-5

July Dorion-Thibaudieu, Durocher Y, Gregory De Crescenzo. Quantification and simultaneous evaluation of the bioactivity of antibody produced in CHO cell culture—The use of the ectodomain of FcγRI and surface plasmon resonance-based biosensor. *Molecular Immunology*. 2017;82:46-49. doi:10.1016/j.molimm.2016.12.017

Immunogenicity

Yu X, Orr CM, Chan C, et al. Reducing affinity as a strategy to boost immunomodulatory antibody agonism. *Nature*. 2023;614(7948):539-547. doi:10.1038/s41586-022-05673-2

Shibata H, Nishimura K, Miyama C, et al. Comparison of different immunoassay methods to detect human anti-drug antibody using the WHO erythropoietin antibody reference panel for analytes. *Journal of Immunological Methods*. 2018;452:73-77. doi:10.1016/j.jim.2017.09.009

Gibbs E, Karim ME, Oger J. Antibody dissociation rates are predictive of neutralizing antibody (NAb) course: A comparison of interferon beta-1b-treated Multiple Sclerosis (MS) patients with transient versus sustained NABs. *Clinical Immunology*. 2015;157(1):91-101. doi:10.1016/j.clim.2014.12.005

Guidelines

Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product Guidance for Industry.; 2016. <https://www.fda.gov/media/88622/download>

Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry.; 2015. <https://www.fda.gov/media/135612/download>

Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry.; 2015. <https://www.fda.gov/media/82647/download>

Structure function

Dobrovodský D, Primo CD. Do conformational changes contribute to the surface plasmon resonance signal? *Biosensors and Bioelectronics*. 2023;232:115296-115296. doi:10.1016/j.bios.2023.115296

Cook AD, Carrington M, Higgins MK. Molecular mechanism of complement inhibition by the trypanosome receptor ISG65. *eLife*. 2023;12. doi:10.7554/elife.88960

Miller PG, Sathappa M, Moroco JA, et al. Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state. *Nature Communications*. 2022;13(1). doi:10.1038/s41467-022-30463-9

Chang W, Altman MD, Lesburg CA, et al. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer. *Journal of Medicinal Chemistry*. 2022;65(7):5675-5689. doi:10.1021/acs.jmedchem.1c02197

Kling A, Lukat P, Almeida DV, et al. Targeting DnaN for tuberculosis therapy using novel griselimycins. *Science*. 2015;348(6239):1106-1112. doi:https://doi.org/10.1126/science.aaa46906. Müller M, Hopfner KP, Witte G. cldilAMP recognition by *Staphylococcus aureus* PstA. *FEBS Letters*. 2014;589(1):45-51. doi:10.1016/j.febslet.2014.11.022

Rechlin C, Scheer F, Terwesten F, et al. Price for Opening the Transient Specificity Pocket in Human Aldose Reductase upon Ligand Binding: Structural, Thermodynamic, Kinetic, and Computational Analysis. *ACS chemical biology*. 2017;12(5):1397-1415. doi:10.1021/acschembio.7b00062

Protein-DNA binding

Bruekner SR, Pieters W, Fish A, et al. Unexpected moves: a conformational change in MutSα enables high-affinity DNA mismatch binding. *Nucleic Acids Research*. 2023;51(3):1173-1188. doi:10.1093/nar/gkad015

Vaidyanathan VG, Xu L, Cho BP. Binary and Ternary Binding Affinities between Exonuclease-Deficient Klenow Fragment (Kf-exo-) and Various Arylamine DNA Lesions Characterized by Surface Plasmon Resonance. *Chemical Research in Toxicology*. 2012;25(8):1568-1570. doi:10.1021/tx300289d

Rollins MF, Schuman JT, Paulus K, Bukhari HST, Wiedenheft B. Mechanism of foreign DNA recognition by a CRISPR RNA-guided surveillance complex from *Pseudomonas aeruginosa*. *Nucleic Acids Research*. 2015;43(4):2216-2222. doi:10.1093/nar/gkv094

Groothuizen FS, Fish A, Petoukhov MV, et al. Using stable MutS dimers and tetramers to quantitatively analyze DNA mismatch recognition and sliding clamp formation. *Nucleic Acids Research*. 2013;41(17):8166-8181. doi:10.1093/nar/gkt582

Membrane proteins

Review

Patching SG. Surface plasmon resonance spectroscopy for characterisation of membrane protein–ligand interactions and its potential for drug discovery. *Biochimica et Biophysica Acta (BBA) - Biomembranes*. 2014;1838(1):43-55. doi:10.1016/j.bbamem.2013.04.028

Chu R, Reczek D, Brondyk W. Capture-stabilize approach for membrane protein SPR assays. *Scientific Reports*. 2014;4(1). doi:10.1038/srep07360

Nanodiscs

Bocquet N, Kohler J, Hug MN, et al. Real-time monitoring of binding events on a thermostabilized human A2A receptor embedded in a lipid bilayer by surface plasmon resonance. *Biochimica Et Biophysica Acta*. 2015;1848(5):1224-1233. doi:10.1016/j.bbame.2015.02.014

Adamson RJ, Watts A. Kinetics of the early events of GPCR signalling. *FEBS Letters*. 2014;588(24):4701-4707. doi:10.1016/j.febslet.2014.10.043

Harding PJ, Hadingham TC, McDonnell JM, Watts A. Direct analysis of a GPCR-agonist interaction by surface plasmon resonance. *European Biophysics Journal*. 2006;35(8):709-712. doi:10.1007/s00249-006-0070-x

Liposomes

Schillinger AS, Cédric Grauffel, Khan HM, Øyvind Halskau, Reuter N. Two homologous neutrophil serine proteases bind to POPC vesicles with different affinities: When aromatic amino acids matter. *Biochimica et Biophysica Acta (BBA) - Biomembranes*. 2014;1838(12):3191-3202. doi:10.1016/j.bbame.2014.09.003

Membrane targets

Bonvicini G, Singh SB, Nygren P, et al. Comparing in vitro affinity measurements of antibodies to TfR1: Surface plasmon resonance versus on-cell affinity. *Analytical Biochemistry*. 2023;686:115406-115406. doi:10.1016/j.ab.2023.115406

Shepherd CE, Robinson SM, Berizzi A, et al. Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments. *ACS Med Chem Lett*. 2022;13(7):1172-1181. doi:10.1021/acsmedchemlett.2c00099

Chu R, Reczek D, Brondyk W. Capture-stabilize approach for membrane protein SPR assays. *Scientific Reports*. 2014;4(1). doi:10.1038/srep07360

Sharma P, Plant M, Lam SK, Chen Q. Kinetic analysis of antibody binding to integral membrane proteins stabilized in SMALPs. *BBA Advances*. 2021;1:100022-100022. doi:10.1016/j.bbadva.2021.100022

Ogura T, Tanaka Y, Toyoda H. Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. *Analytical Biochemistry*. 2016;508:73-77. doi:10.1016/j.ab.2016.06.021

Vaccines

Review

Hearty S, Conroy P, B. Vijayalakshmi Ayyar, Byrne BJ, O'Kennedy R. Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends. *Expert Rev Vaccines*. 2010;9(6):645-664. doi:10.1586/erv.10.52

Van Regenmortel MH. Binding measurements as surrogate biological assays: surface plasmon resonance biosensors for characterizing vaccine components. *Developments in biologicals*. 2000;103:69-74. <https://www.ncbi.nlm.nih.gov/pubmed/11214255>

Research and vaccine development

Hein S, Mhedhbi I, Zahn T, et al. Quantitative and Qualitative Difference in Antibody Response against Omicron and Ancestral SARS-CoV-2 after Third and Fourth Vaccination. *Vaccines*. 2022;10(5):796. doi:10.3390/vaccines10050796

Baker AT, Boyd RJ, Sarkar D, et al. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. *Science Advances*. 2021;7(49). doi:10.1126/sciadv.abl8213

Dai L, Song J, Lu X, et al. Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. *Cell Host & Microbe*. 2016;19(5):696-704. doi:10.1016/j.chom.2016.04.013

Franco Pissani, Malherbe DC, Schuman JT, et al. Improvement of antibody responses by HIV envelope DNA and protein co-immunization. *Vaccine*. 2013;32(4):507-513. doi:10.1016/j.vaccine.2013.11.022

Lahoud MH, Fatma Ahmet, Zhang J, et al. DEC-205 is a cell surface receptor for CpG oligonucleotides. *Proc Natl Acad Sci U S A*. 2012;109(40):16270-16275. doi:10.1073/pnas.1208796109

Kovacs JM, Nkolola JP, Peng H, et al. HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120. *Proceedings of the National Academy of Sciences*. 2012;109(30):12111-12116. doi:10.1073/pnas.1204533109

Malito E, Bursulaya B, Chen C, et al. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197. *Proceedings of the National Academy of Sciences*. 2012;109(14):5229-5234. doi:10.1073/pnas.1201964109

Lee H, Ren J, Nocadello S, et al. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. *Antiviral Research*. 2017;139:49-58. doi:10.1016/j.antiviral.2016.12.016

Process optimization, process control and product stability

Manin C, Naville S, Gueugnon M, Dupuy M, Bravo de Alba Y, Adam O. Method for the simultaneous assay of the different poliovirus types using surface plasmon resonance technology. *Vaccine*. 2013;31(7):1034-1039. doi:10.1016/j.vaccine.2012.12.046

Towne V, Zhao Q, Brown M, Finnefrock AC. Pairwise antibody footprinting using surface plasmon resonance technology to characterize human papillomavirus type 16 virus-like particles with direct anti-HPV antibody immobilization. *Journal of Immunological Methods*. 2013;388(1-2):1-7. doi:10.1016/j.jim.2012.11.005

Mulder AM, Carragher B, Towne V, et al. Toolbox for Non-Intrusive Structural and Functional Analysis of Recombinant VLP Based Vaccines: A Case Study with Hepatitis B Vaccine. *PLOS ONE*. 2012;7(4):e33235-e33235. doi:10.1371/journal.pone.0033235

Westdijk J, Brugmans D, Martin J, et al. Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines. *Vaccine*. 2011;29(18):3390-3397. doi:10.1016/j.vaccine.2011.02.085

Zhao Q, Towne V, Brown M, et al. In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: Multifaceted biochemical and immunochemical characterization. *Vaccine*. 2011;29(45):7936-7941. doi:10.1016/j.vaccine.2011.08.070

Small molecules and fragments

Review

Kaminski T, Gunnarsson A, Geschwindner S. Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery. *ACS Sensors*. 2016;2(1):10-15. doi:10.1021/acssensors.6b00735

Renaud JP, Chung C, Danielson UH, et al. Biophysics in drug discovery: impact, challenges and opportunities. *Nature Reviews Drug Discovery*. 2016;15(10):679-698. doi:10.1038/nrd.2016.123

Erlanson DA, Fesik SW, Hubbard RE, Jahnke W, Jhoti H. Twenty years on: the impact of fragments on drug discovery. *Nature Reviews Drug Discovery*. 2016;15(9):605-619. doi:10.1038/nrd.2016.109

Andersson K, Karlsson R, Löfås S, Franklin G, Hämäläinen MD. Label-free kinetic binding data as a decisive element in drug discovery. *Expert Opinion on Drug Discovery*. 2006;1(5):439-446. doi:10.1517/17460441.1.5.439

Small molecule screening

Huber S, Casagrande F, Hug MN, et al. SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands. Karnik SS, ed. *PLOS ONE*. 2017;12(5):e0175842. doi:10.1371/journal.pone.0175842

Fragment screening

FitzGerald EA, Vagry D, Giulia Opassi, et al. Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors. *SLAS DISCOVERY*. 2023;29(1):40-51. doi:10.1016/j.slasd.2023.09.001

Huber S, Casagrande F, Hug MN, et al. SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands. Karnik SS, ed. *PLOS ONE*. 2017;12(5):e0175842. doi:10.1371/journal.pone.0175842

Li XP, Harijan RK, Cao B, et al. Synthesis and Structural Characterization of Ricin Inhibitors Targeting Ribosome Binding Using Fragment-Based Methods and Structure-Based Design. *Journal of Medicinal Chemistry*. 2021;64(20):15334-15348. doi:10.1021/acs.jmedchem.1c01370

Structure kinetic relation

Bonagas N, Gustafsson NMS, Henriksson M, et al. Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress. *Nature Cancer*. 2022;3(2):156-172. doi:10.1038/s43018-022-00331-y

Luttens A, Gullberg H, Abdurakhmanov E, et al. Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses. *Journal of the American Chemical Society*. 2022;144(7):2905-2920. doi:10.1021/jacs.1c08402

Zhukov A, Andrews SP, Errey JC, et al. Biophysical Mapping of the Adenosine A2A Receptor. *Journal of Medicinal Chemistry*. 2011;54(13):4312-4323. doi:10.1021/jm2003798

Uitdehaag JCM, de Man J, Willemsen-Seegers N, et al. Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. *Journal of Molecular Biology*. 2017;429(14):2211-2230. doi:10.1016/j.jmb.2017.05.014

Cramer J, Krimmer SG, Fridh V, et al. Elucidating the Origin of Long Residence Time Binding for Inhibitors of the Metalloprotease Thermolysin. *ACS Chemical Biology*. 2016;12(1):225-233. doi:10.1021/acscchembio.6b00979

Krimmer SG, Cramer J, Betz M, et al. Rational Design of Thermodynamic and Kinetic Binding Profiles by Optimizing Surface Water Networks Coating Protein-Bound Ligands. *Journal of Medicinal Chemistry*. 2016;59(23):10530-10548. doi:10.1021/acs.jmedchem.6b00998

Heinrich T, Jeyaprakashnarayanan Seenisamy, Lourdasamy Emmanuvel, et al. Fragment-Based Discovery of New Highly Substituted 1H-Pyrrolo[2,3-b]- and 3H-Imidazo[4,5-b]-Pyridines as Focal Adhesion Kinase Inhibitors. *Journal of Medicinal Chemistry*. 2013;56(3):1160-1170. doi:10.1021/jm3016014

Danielson UH. Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. *Future Medicinal Chemistry*. 2009;1(8):1399-1414. doi:10.4155/fmc.09.100

Andersson K, Hämäläinen MD. Replacing affinity with binding kinetics in QSAR studies resolves otherwise confounded effects. *Journal of Chemometrics*. 2006;20(8-10):370-375. doi:10.1002/cem.1010

Per-Olof Markgren, Schaal W, M. Hämäläinen, et al. Relationships between Structure and Interaction Kinetics for HIV-1 Protease Inhibitors. *Journal of Medicinal Chemistry*. 2002;45(25):5430-5439. doi:10.1021/jm0208370

Willemsen-Seegers N, Joost C.M. Uitdehaag, Martine B.W. Prinsen, et al. Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance. *Journal of Molecular Biology*. 2016;429(4):574-586. doi:10.1016/j.jmb.2016.12.019

Kinetic and biological function

Ana, Lemos AR, Busse P, et al. Extract2Chip—Bypassing Protein Purification in Drug Discovery Using Surface Plasmon Resonance. *Biosensors*. 2023;13(10):913-913. doi:10.3390/bios13100913

He Y, Grether U, Taddio MF, et al. Multi-parameter optimization: Development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain. *European Journal of Medicinal Chemistry*. 2022;243:114750-114750. doi:10.1016/j.ejmech.2022.114750

Hochheiser IV, Pils M, Hagelueken G, et al. Structure of the NLRP3 decamer bound to the cytokine release inhibitor CRID3. *Nature*. 2022;604(7904):184-189. doi:10.1038/s41586-022-04467-w

Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. *Nature*. 2021;593(7860):597-601. doi:https://doi.org/10.1038/s41586-021-03536-w5.Arney JW, Weeks KM. RNA-Ligand Interactions Quantified by Surface Plasmon Resonance with Reference Subtraction. *Biochemistry*. 2022;61(15):1625-1632. doi:10.1021/acs.biochem.2c00177

Dietrich JD, Longenecker KL, Wilson NS, et al. Development of Orally Efficacious Allosteric Inhibitors of TNF α via Fragment-Based Drug Design. *Journal of Medicinal Chemistry*. 2020;64(1):417-429. doi:10.1021/acs.jmedchem.0c01280

Diya Lv, Xu J, Qi M, et al. A strategy of screening and binding analysis of bioactive components from traditional Chinese medicine based on surface plasmon resonance biosensor. *Journal of Pharmaceutical Analysis*. 2021;12(3):500-508. doi:10.1016/j.jpha.2021.11.006

Ogura T, Tanaka Y, Toyoda H. Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target. *Analytical Biochemistry*. 2016;508:73-77. doi:10.1016/j.ab.2016.06.021

Lei H, Jones C, Zhu T, et al. Identification of B. anthracis N5-carboxyaminoimidazole ribonucleotide mutase (PurE) active site binding compounds via fragment library screening. *Bioorganic & Medicinal Chemistry*. 2016;24(4):596-605. doi:10.1016/j.bmc.2015.12.029

Jones AM, Westwood IM, Osborne JD, et al. A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms. *Scientific Reports*. 2016;6(1). doi:10.1038/srep34701

Segala E, Errey JC, Fiez-Vandal C, Zhukov A, Cooke RM. Biosensor-based affinities and binding kinetics of small molecule antagonists to the adenosine A2A receptor reconstituted in HDL like particles. *FEBS Letters*. 2015;589(13):1399-1405. doi:10.1016/j.febslet.2015.04.030

Dahl G, Akerud T. Pharmacokinetics and the drug-target residence time concept. *Drug Discovery Today*. 2013;18(15-16):697-707. doi:https://doi.org/10.1016/j.drudis.2013.02.01013. Swinney DC, Anthony J. How were new medicines discovered? *Nature Reviews Drug Discovery*. 2011;10(7):507-519. doi:10.1038/nrd3480

Tummino PJ, Copeland RA. Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function. *Biochemistry*. 2008;47(20):5481-5492. doi:10.1021/bi8002023

Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. *Nature Reviews Drug Discovery*. 2006;5(9):730-739. doi:https://doi.org/10.1038/nrd208216. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? *Nature Reviews Drug Discovery*. 2004;3(9):801-808. doi:10.1038/nrd1500

cytiva.com/biacore

Cytiva and the Drop logo are trademarks of Life Sciences IP Holdings Corporation or an affiliate doing business as Cytiva. Biacore is a trademark of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. Any other third-party trademarks are property of their respective owners.

© 2024 Cytiva

For local office contact information, visit cytiva.com/contact

CY48116-18Oct24-FL

